Buy G-NIB : Gefitinib 250 mg Tablet 30’S Online

Description

Description:

G-NIB is a medication manufactured by BDR Pharmaceuticals International Pvt. Ltd., containing the active ingredient Gefitinib. Each tablet typically contains 250 mg of Gefitinib. Gefitinib belongs to a class of medications called tyrosine kinase inhibitors (TKIs), which are used for the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC).

Indications:

G-NIB is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has certain mutations in the epidermal growth factor receptor (EGFR) gene. It is specifically used for the following conditions:

1. First-Line Treatment: G-NIB is used as first-line treatment in patients with NSCLC that harbors activating mutations of the EGFR gene, including exon 19 deletions or exon 21 (L858R) substitution mutations.
2. Second-Line Treatment: G-NIB may also be used as subsequent therapy in patients with NSCLC who have progressed on or after chemotherapy.

How It Works:

Gefitinib works by inhibiting the activity of the epidermal growth factor receptor (EGFR), a protein that is overexpressed or mutated in certain types of cancer cells, particularly NSCLC. By blocking the activity of EGFR, Gefitinib helps to slow down or stop the growth and spread of cancer cells, leading to tumor shrinkage and improved survival outcomes.

Dosage and Administration:

The recommended dosage of G-NIB varies depending on the patient’s medical condition, treatment response, and other factors. It is usually taken orally once daily, with or without food, as directed by a healthcare professional. The tablets should be swallowed whole with a glass of water and should not be crushed, chewed, or broken.

Possible Side Effects:

Common side effects of G-NIB may include:

1. Skin Rash: Rash or skin irritation is a common side effect reported by patients taking Gefitinib.
2. Diarrhea: Gastrointestinal symptoms such as diarrhea, nausea, vomiting, and abdominal pain may occur.
3. Fatigue: Feeling tired or weak is a common side effect reported during treatment with Gefitinib.
4. Decreased Appetite: Some patients may experience a decrease in appetite or weight loss.
5. Liver Toxicity: Gefitinib can cause liver toxicity, leading to elevated liver enzymes and hepatotoxicity.
6. Interstitial Lung Disease: Rarely, Gefitinib can cause interstitial lung disease (ILD), a serious lung condition characterized by inflammation and scarring of lung tissue.

Warnings and Precautions:

1. Pulmonary Toxicity: Patients should be monitored for signs and symptoms of interstitial lung disease (ILD), such as cough, dyspnea, and fever. Treatment should be discontinued if ILD is suspected.
2. Hepatotoxicity: Liver function tests should be performed before starting treatment with Gefitinib and monitored regularly during treatment.
3. Skin Reactions: Patients should be advised to report any skin rash or severe skin reactions to their healthcare provider.
4. Pregnancy and Breastfeeding: Gefitinib can cause fetal harm and should not be used during pregnancy. Women of childbearing age should use effective contraception during treatment and for a period after discontinuation of therapy. It is not known whether Gefitinib passes into breast milk, so breastfeeding is not recommended during treatment.

G-NIB by BDR Pharmaceuticals International Pvt. Ltd. is a prescription medication used for the treatment of non-small cell lung cancer (NSCLC) with certain mutations in the EGFR gene. Patients should follow their healthcare provider’s instructions regarding dosage, administration, and monitoring for adverse effects. Any concerns or potential side effects should be discussed with a healthcare professional.